Global Tuberculosis Targets and Milestones Set for 2016-2035: Definition and Rationale

Overview

Journal Int J Tuberc Lung Dis

Specialty Pulmonary Medicine

Date 2018 Jun 20

PMID 29914597

Citations 48

Authors

K Floyd

P Glaziou

R M G J Houben

T Sumner

R G White

M Raviglione

Affiliations

Soon will be listed here.

Abstract

Background: Global tuberculosis (TB) targets were set as part of the World Health Organization's End TB Strategy (2016-2035) and the Sustainable Development Goals (2016-2030).

Objective: To define and explain the rationale for these targets.

Design: Scenarios for plausible reductions in TB deaths and cases were developed using empirical evidence from best-performing countries and modelling of the scale-up of under-used interventions and hypothetical TB vaccines. Results were discussed at consultations in 2012 and 2013. A final proposal was presented to the World Health Assembly in 2014 and unanimously endorsed by all Member States.

Results: The 2030 targets are a 90% reduction in TB deaths and 80% reduction in TB incidence compared with 2015 levels. The 2035 targets are for reductions of 95% and 90%, respectively. A third target-that no TB-affected households experience catastrophic costs due to the disease by 2020-was also agreed.

Conclusion: The global TB targets and milestones set for the period 2016-2035 are ambitious. Achieving them requires concerted action on several fronts, but two things are fundamental: 1) progress towards universal health coverage to ensure that everyone with TB can access high-quality treatment; and 2) substantial investment in research and development for new tools to prevent TB disease among the approximately 1.7 billion people infected.

Citing Articles

Clustering and modeling joint-trajectories of HIV/AIDS and tuberculosis mortality rates using bayesian multi-process latent growth model: A global study from 1990 to 2021.

Mobaderi T, Kazemnejad A, Salehi M BMC Infect Dis. 2025; 25(1):330.

PMID: 40065233 PMC: 11892175. DOI: 10.1186/s12879-025-10715-x.

Estimating the health and macroeconomic burdens of tuberculosis in India, 2021-2040: A fully integrated modelling study.

Keogh-Brown M, Sumner T, Sweeney S, Vassall A, Jensen H PLoS Med. 2024; 21(12):e1004491.

PMID: 39666614 PMC: 11637336. DOI: 10.1371/journal.pmed.1004491.

Unlocking the potential of miRNAs in detecting pulmonary tuberculosis: prospects and pitfalls.

Arya R, Kumar S, Vinetz J, Kim J, Chaurasia R Expert Rev Mol Med. 2024; 26:e32.

PMID: 39639643 PMC: 11629464. DOI: 10.1017/erm.2024.29.

Detection of Rifampicin Resistance rpoB Gene Using GeneXpert MTB/RIF Assay in Pulmonary Tuberculosis Cases at Debre Tabor Comprehensive Specialized Hospital, Northwest Ethiopia.

Sharew B, Berhan A, Almaw A, Erkihun M, Tiruneh T, Kiros T J Clin Lab Anal. 2024; 38(22):e25111.

PMID: 39387506 PMC: 11584306. DOI: 10.1002/jcla.25111.

Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity.

Shi Z, Zhou L, Wang X, Zhang Z, Kong L, Zhang Y Arch Microbiol. 2024; 206(8):352.

PMID: 39012499 DOI: 10.1007/s00203-024-04033-0.

References

Steingart K, Schiller I, Horne D, Pai M, Boehme C, Dendukuri N . Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014; (1):CD009593. PMC: 4470349. DOI: 10.1002/14651858.CD009593.pub3. View

Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias H . WHO's new end TB strategy. Lancet. 2015; 385(9979):1799-1801. DOI: 10.1016/S0140-6736(15)60570-0. View

Dye C, Bassili A, Bierrenbach A, Broekmans J, Chadha V, Glaziou P . Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis. 2008; 8(4):233-43. DOI: 10.1016/S1473-3099(07)70291-8. View

Enarson D, Grzybowski S . Incidence of active tuberculosis in the native population of Canada. CMAJ. 1986; 134(10):1149-52. PMC: 1491042. View

STYBLO K, Meijer J, Sutherland I . [The transmission of tubercle bacilli: its trend in a human population]. Bull World Health Organ. 1969; 41(1):137-78. PMC: 2427401. View

Latko B, Temporao J, Frenk J, Evans T, Chen L, Pablos-Mendez A . The growing movement for universal health coverage. Lancet. 2010; 377(9784):2161-3. DOI: 10.1016/S0140-6736(10)62006-5. View

Blower S, McLean A, Porco T, Small P, Hopewell P, Sanchez M . The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med. 1995; 1(8):815-21. DOI: 10.1038/nm0895-815. View

Raviglione M, Ditiu L . Setting new targets in the fight against tuberculosis. Nat Med. 2013; 19(3):263. DOI: 10.1038/nm.3129. View

Suthar A, Lawn S, Del Amo J, Getahun H, Dye C, Sculier D . Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012; 9(7):e1001270. PMC: 3404110. DOI: 10.1371/journal.pmed.1001270. View

10.

Behr M, Warren S, Salamon H, Hopewell P, Ponce De Leon A, Daley C . Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999; 353(9151):444-9. DOI: 10.1016/s0140-6736(98)03406-0. View

11.

Grzybowski S, STYBLO K, Dorken E . Tuberculosis in Eskimos. Tubercle. 1976; 57(4 Suppl):S1-58. DOI: 10.1016/0041-3879(76)90059-3. View

12.

Boerma T, Eozenou P, Evans D, Evans T, Kieny M, Wagstaff A . Monitoring progress towards universal health coverage at country and global levels. PLoS Med. 2014; 11(9):e1001731. PMC: 4171369. DOI: 10.1371/journal.pmed.1001731. View

13.

Akolo C, Adetifa I, Shepperd S, Volmink J . Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010; (1):CD000171. PMC: 7043303. DOI: 10.1002/14651858.CD000171.pub3. View

14.

Raviglione M, Uplekar M . WHO's new Stop TB Strategy. Lancet. 2006; 367(9514):952-5. DOI: 10.1016/S0140-6736(06)68392-X. View

15.

Houben R, Sumner T, Grant A, White R . Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A. 2014; 111(14):5325-30. PMC: 3986199. DOI: 10.1073/pnas.1317660111. View

16.

Evans D, Etienne C . Health systems financing and the path to universal coverage. Bull World Health Organ. 2010; 88(6):402. PMC: 2878164. DOI: 10.2471/BLT.10.078741. View

17.

Abu-Raddad L, Sabatelli L, Achterberg J, Sugimoto J, Longini Jr I, Dye C . Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A. 2009; 106(33):13980-5. PMC: 2720405. DOI: 10.1073/pnas.0901720106. View

18.

Smieja M, Marchetti C, Cook D, Smaill F . Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000; (2):CD001363. PMC: 6532737. DOI: 10.1002/14651858.CD001363. View

19.

Menzies N, Cohen T, Lin H, Murray M, Salomon J . Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med. 2012; 9(11):e1001347. PMC: 3502465. DOI: 10.1371/journal.pmed.1001347. View

20.

Dye C, Garnett G, Sleeman K, Williams B . Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet. 1998; 352(9144):1886-91. DOI: 10.1016/s0140-6736(98)03199-7. View